Geneuro Provides Access to Presentations from HERVs and Disease Workshop Held in Washington, DC

GENEVA--()--Regulatory News:

GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, including multiple sclerosis (MS), today provided access to research on human endogenous retroviruses (HERVs) and their impact on neurological pathologies. At the recent 2nd International Workshop on Human Endogenous Retroviruses and Disease, held in Washington, DC, experts from around the world gathered to discuss topics focusing on nervous system diseases, such as HERV-W envelope protein (MSRV-Env) and its role in multiple sclerosis (MS), how activated HERV-K and its envelope protein cause pathogenic effects relevant for amyotrophic lateral sclerosis and the potential link of HERVs to psychoses. Past, ongoing and future therapeutic strategies in clinical trials targeting HERVs in these diseases were also presented and discussed between the clinicians and scientific experts.

Hervé Perron, Chief Scientific Officer of GeNeuro, said: “The HERV and Disease meeting provides a unique opportunity for scientific and clinical experts to share their knowledge and experience in the field. Momentum in HERV medical research as well as therapeutic development is now building rapidly.”

The presentations of the HERV & Disease International Workshop can be found at www.hervanddisease.com/program/

GeNeuro is conducting a Phase 2b clinical study with GNbAC1, a monoclonal antibody designed to neutralize MSRV-Env, a pathogenic protein that has been associated with both the inflammatory and neurodegenerative components of the disease. GeNeuro expects top-line results from this study, made in partnership with Servier, to be available early in the fourth quarter 2017.

For more information about the 2017 HERVs & Disease Workshop, visit: www.hervanddisease.com

About GeNeuro

GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in France at sites in Archamps, Haute-Savoie and in Lyon. It has 30 employees and rights to 16 patent families protecting its technology.

For more information, visit: www.geneuro.com

Disclaimer

This press release contains certain forward - looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

GeNeuro
Jesús Martin-Garcia, +41 22 552 48 00
Chairman and CEO
investors@geneuro.com
or
NewCap (France)
Julien Perez (investors)
+33 1 44 71 98 52
or
Nicolas Merigeau (media)
+33 1 44 71 94 98
geneuro@newcap.eu
or
Halsin Partners
Mike Sinclair (media)
+44 20 7318 2955
msinclair@halsin.com
or
LifeSci Advisors
Chris Maggos (investors)
+1 646 597 6970
+41 79 367 6254
chris@lifesciadvisors.com

Contacts

GeNeuro
Jesús Martin-Garcia, +41 22 552 48 00
Chairman and CEO
investors@geneuro.com
or
NewCap (France)
Julien Perez (investors)
+33 1 44 71 98 52
or
Nicolas Merigeau (media)
+33 1 44 71 94 98
geneuro@newcap.eu
or
Halsin Partners
Mike Sinclair (media)
+44 20 7318 2955
msinclair@halsin.com
or
LifeSci Advisors
Chris Maggos (investors)
+1 646 597 6970
+41 79 367 6254
chris@lifesciadvisors.com